Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
If you have been living with an autoimmune disease that no longer responds adequately to conventional treatment, you may have encountered an unfamiliar term in recent medical research: CAR-T therapy for autoimmune disease.
CAR-T has already changed the treatment landscape for certain blood cancers. Now researchers are asking whether the same technology can be used for a very different problem: an immune system that is attacking the patient's own body.
That research is moving quickly. Early studies have reported substantial responses in people with severe, treatment-refractory systemic lupus erythematosus, systemic sclerosis and inflammatory myopathies. But this is also an area where families need to separate promising research from established treatment. Most autoimmune CAR-T studies remain small and early-stage, and long-term safety and durability still need to be established.
Key Takeaways |
|
What is CAR-T Therapy for Autoimmune Disease?
CAR-T stands for chimeric antigen receptor T-cell therapy.
The basic idea is to take T cells, a type of immune cell, and genetically modify them so they recognize a particular target. The modified cells are then expanded and given back to the patient.
In cancer, CAR-T cells are designed to recognize and attack cancer cells. In autoimmune disease, researchers are taking a different approach.
Many autoimmune diseases involve B cells, which can produce autoantibodies and contribute to abnormal immune signaling. A number of experimental CAR-T approaches therefore target CD19, a marker found on many B cells.
The intention is not simply to suppress inflammation temporarily. Researchers are investigating whether very deep B-cell depletion can remove the immune cells driving the disease and allow the immune system to rebuild with a different repertoire.
This concept is sometimes described as an immune-system reset.
Importantly, "reset" does not mean that every autoimmune disease can currently be cured. It describes the biological theory behind the treatment strategy.
Which Autoimmune Diseases are Being Studied with CAR-T?
Research is currently concentrated on autoimmune diseases in which B cells and autoantibodies play an important role.
The best-known areas include:
Systemic Lupus Erythematosus
Systemic lupus erythematosus, or SLE, is currently one of the most extensively studied autoimmune diseases for CAR-T therapy.
In a 2025 phase 1 study from China, researchers treated eight people with moderately to severely active SLE using the CD19 CAR-T product relmacabtagene autoleucel (relma-cel). All patients achieved an SRI response; four met DORIS remission criteria and seven reached the Lupus Low Disease Activity State within one to four months.
A separate phase 1 study published later in 2025 also evaluated relma-cel in eight women with active SLE and reported improvements in disease activity, with five patients meeting DORIS remission criteria at follow-up.
These are encouraging findings, but eight patients is still a very small study population.
Systemic Sclerosis
Systemic sclerosis, sometimes called scleroderma, is another condition being investigated.
A case series published in The Lancet Rheumatology described six patients with severe diffuse systemic sclerosis who had inadequate responses to at least two previous treatments and subsequently received CD19-targeted CAR-T therapy.
Systemic sclerosis is particularly important to study because inflammation and immune abnormalities can eventually cause irreversible organ damage. That makes both timing and patient selection important considerations.
Idiopathic Inflammatory Myopathies
CAR-T therapy is also being investigated in inflammatory muscle diseases such as dermatomyositis and polymyositis.
The 2026 CASTLE phase 1/2a basket trial included patients with SLE, systemic sclerosis and idiopathic inflammatory myopathies. Twenty-four patients were enrolled across the three disease groups.
Other Autoimmune Diseases
Researchers are investigating CAR-T approaches for additional conditions, including Sjögren's disease, rheumatoid arthritis, autoimmune vasculitis and antiphospholipid syndrome.
A registered Chinese study of a universal CAR-T product, BRL-301, has included refractory SLE, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, ANCA-associated systemic vasculitis and antiphospholipid syndrome.
This does not mean CAR-T is currently an established treatment for all of these conditions. It means researchers are studying whether the approach could have a role.
Does CAR-T Actually Work for Autoimmune Disease?
The early results are promising, but the evidence needs to be read carefully.
One of the most important recent studies is the CASTLE basket trial, published in Nature Medicine in January 2026. It evaluated CD19 CAR-T in people with severe, treatment-resistant SLE, systemic sclerosis and idiopathic inflammatory myopathies.
Twenty-four patients were enrolled: 10 with SLE, nine with systemic sclerosis and five with inflammatory myopathies. The predefined efficacy endpoint was reached in 22 of the 24 patients. Nine of the 10 SLE patients achieved DORIS remission, all nine systemic-sclerosis patients met the study's no-progression endpoint, and four of five inflammatory-myopathy patients achieved an ACR major or moderate response.
The same study reported that patients remained free of glucocorticoids and other immunosuppressive treatment during the 24-week observation period, with follow-up extending beyond six months for many participants.
Another 2025 study investigated dual CD19/BCMA CAR-T in treatment-refractory SLE. Fifteen patients were treated, and 12 met both LLDAS and DORIS remission criteria by week 12. The researchers reported grade 1 cytokine release syndrome in most patients but no neurotoxicity or treatment-related deaths in that study.
These results help explain why CAR-T has attracted so much attention in autoimmune medicine.
But they do not establish CAR-T as a universally effective treatment. The studies are relatively small, many lack randomized control groups, and researchers are still determining which patients benefit, how durable the responses are, and what the long-term risks may be.
What Are the Risks of CAR-T Therapy for Autoimmune Disease?
This is one of the most important questions to ask before considering treatment.
CAR-T is a complex cellular therapy. Even when it is being used for autoimmune disease rather than cancer, patients may need lymphodepleting chemotherapy before the CAR-T infusion.
Potential complications include:
Cytokine release syndrome (CRS), which can cause fever, low blood pressure and other systemic inflammatory symptoms.
Neurotoxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS).
Low blood-cell counts following lymphodepletion.
Infections, particularly while immune-cell populations are recovering.
Low immunoglobulin levels, because B-cell depletion can affect normal antibody production.
Rare but serious inflammatory complications, including immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome.
In the Chinese relma-cel SLE phase 1 study, all eight patients experienced cytopenia, seven experienced CRS and five developed hypogammaglobulinemia. No ICANS was reported, although one patient experienced a rare severe immune-related complication.
This is why autoimmune CAR-T should not be approached as an ordinary outpatient treatment. The treating center needs appropriate cellular-therapy infrastructure, monitoring and emergency support.
Is CAR-T for Autoimmune Disease Approved or Experimental?
For most autoimmune diseases, patients should assume that CAR-T remains investigational unless a treating center confirms otherwise under a specific regulatory pathway.
This distinction is extremely important.
A CAR-T product may be commercially approved for a particular cancer indication while simultaneously being investigated for an autoimmune disease in a clinical trial.
For example, relma-cel is an anti-CD19 CAR-T product approved in China for certain blood-cancer indications. Researchers have separately studied the product in SLE. The fact that the product is approved for cancer does not automatically mean it is approved for routine treatment of lupus.
There are also different ways patients may access experimental cellular therapies, depending on the country and program. These can include clinical trials and other regulated access pathways.
For an international patient, the relevant question is therefore not simply:
"Does this country offer CAR-T?"
It is:
"Is there a legitimate program that is currently accepting patients with my specific autoimmune disease, and am I medically eligible?"
Could Autoimmune CAR-T Be Available in China?
China has become an important center for research into CAR-T therapy for autoimmune disease.
Chinese investigators have published clinical data involving CD19 CAR-T for SLE, including studies at hospitals in Wuhan and Shanghai.
China has also investigated allogeneic, or donor-derived, CAR-T approaches. A 2025 study from Nanjing reported treatment of three people with severe refractory SLE using healthy-donor-derived CD19-targeting CAR-T cells.
Other Chinese research has explored dual-target CAR-T strategies. A 2025 Nature Medicine study from Zhejiang University investigated combined CD19- and BCMA-targeting CAR-T cells in treatment-refractory SLE.
There is also a registered Chinese study specifically investigating universal CAR-T cells for several refractory autoimmune diseases.
For an international patient, however, availability can change quickly. A study may be scientifically relevant without being open to foreign patients, accepting new participants, or appropriate for a particular disease stage.
That is why a medical-record review should come before making travel arrangements.
How ChinaCureLink Can Help International Patients Explore CAR-T for Autoimmune Disease
For a family considering CAR-T in China, the first step should not be buying a plane ticket.
It should be determining whether there is a medically appropriate pathway at all.
ChinaCureLink can help international patients organize their medical records and explore whether a Chinese hospital or research program may be relevant to their particular diagnosis and treatment history.
1. Reviewing the Medical History
Autoimmune CAR-T is generally being studied in people with severe or treatment-refractory disease. The hospital will need to understand the diagnosis, previous medications, organ involvement, laboratory results, imaging and current disease activity.
ChinaCureLink can help organize this information into a medical case submission for review.
2. Identifying an Appropriate Hospital or Program
The existence of CAR-T research in China does not mean every hospital offers the same program.
The relevant question is whether the patient's disease matches the eligibility requirements of a particular center or clinical program.
ChinaCureLink helps international families communicate with Chinese medical institutions and understand what documentation and evaluation are required.
3. Coordinating the International Treatment Journey
If a hospital confirms that a patient may be eligible for evaluation or treatment, there are practical issues beyond medicine: translation, appointment coordination, medical documentation, travel planning and communication with the treating team.
For families already dealing with a serious illness, having one team coordinate those details can make the process easier to navigate.
The important point is that ChinaCureLink does not promise that CAR-T will be appropriate or available for every autoimmune patient. The receiving medical team must make that determination after reviewing the patient's individual case.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
Frequently Asked Questions
Is CAR-T Therapy Approved for Autoimmune Disease?
CAR-T is established for certain blood cancers, but its use in autoimmune diseases remains largely investigational. Clinical studies are evaluating CAR-T for conditions including lupus, systemic sclerosis and inflammatory myopathies. Patients should confirm the regulatory status and access pathway of any specific program before treatment.
What Autoimmune Diseases Can CAR-T Treat?
Research has focused particularly on systemic lupus erythematosus, systemic sclerosis and idiopathic inflammatory myopathies. Studies are also investigating other B-cell-mediated autoimmune diseases, including Sjögren's disease, rheumatoid arthritis and autoimmune vasculitis. Eligibility depends on the specific study or treatment program.
Is CAR-T a Cure for Lupus?
Current evidence does not establish CAR-T as a guaranteed cure for lupus. Some early studies have reported remission without ongoing immunosuppressive medication in selected patients, which is an important research finding. Larger and longer studies are needed to determine how durable these responses are.
How Does CAR-T Work for Autoimmune Disease?
Many experimental autoimmune CAR-T therapies target CD19, a marker on B cells. The goal is to remove disease-driving B cells deeply enough that the immune system can repopulate with a healthier immune-cell repertoire. This is different from simply suppressing inflammation with conventional medication.
Can International Patients Receive Autoimmune CAR-T Treatment in China?
Some Chinese hospitals and research programs have studied CAR-T for autoimmune diseases, but availability depends on the specific disease, eligibility criteria, regulatory pathway and whether a program is accepting international patients. A medical-record review should be completed before making travel or financial commitments.
What Should I Do Before Considering CAR-T for Autoimmune Disease?
Start with your complete medical history: diagnosis, previous treatments, current medications, laboratory results, imaging and records of organ involvement. A specialist should then determine whether CAR-T research or another advanced treatment pathway is medically appropriate for your particular situation.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
Müller F, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease: A Case Series with Follow-up. New England Journal of Medicine, 2024.New England Journal of Medicine
Shu J, et al. Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus. EClinicalMedicine, 2025. PubMed
Feng J, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus. Nature Medicine, 2025. Nature Medicine
Müller F, et al. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nature Medicine, 2026. Nature Medicine
Auth J, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. The Lancet Rheumatology, 2025. PubMed
Kattamuri L, et al. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatology International, 2025. PubMed
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases — NCT05859997. ClinicalTrials.gov. ClinicalTrials.gov
Comments